secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001326110-26-000057
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio Q1 net product revenue $44.2M, up 168% YoY; ANKTIVA approvals expand; cash $381M
--------------------------------------------------------------------------------

- Q1 2026 net product revenue $44.2M, up 168% YoY ($16.5M) and 15% sequentially from Q4 2025 ($38.3M).
- ANKTIVA unit sales up 168% YoY; approved in 5 jurisdictions covering ~34 countries, including first Asia approval in Macau.
- Cash and marketable securities $380.9M as of March 31, 2026, up from $242.8M at Dec 31, 2025.
- Pivotal BCG-naïve CIS trial fully enrolled; sBLA submission on track for 2026.
- GAAP net loss $632.8M driven by non-cash fair value changes; adjusted net loss $86.2M vs $82.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000057/0001326110-26-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000057/ibrx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer